New Drugs 2012-2013- Pharmacy Technician


  Credits  2

This product is currently out of stock and unavailable.

The FDA approved 35 new drugs in fiscal year 2012 (10/1/2011 – 9/30/2012), the same number as in fiscal year 2011. More than half of these new drugs had received expedited review. Additional drugs were approved during the last 3 months of 2012, including 8 in December alone. The new approvals include some potential blockbusters, but also a number of drugs for rare diseases. A substantial percentage of the new approvals are targeted therapies for advanced cancers. This issue focuses on new drugs that are likely to be encountered in community practice. Among them are 2 long-awaited weight loss drugs – one, a new molecular entity; the other, a combination of 2 previously approved drugs. Others include a second oral factor Xa inhibitor (providing a third alternative to warfarin); a second oral multiple sclerosis drug; a non-anticholinergic drug for overactive bladder; and a short-course topical treatment for actinic keratosis. A second long-acting inhaled anticholinergic, a new treatment for severe hypertriglyceridemia, and a novel agent for chronic constipation are also discussed. Two new rheumatoid arthritis medications – an oral disease-modifying drug with a novel mechanism of action (tofacitinib [Xeljanz®]), and a delayed-release formulation of prednisone (Rayos®) – will be detailed in an upcoming issue.


Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Tech Drug Therapy

Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

Course Accreditation

  • Activity Type:
  • CE Broker
  • Universal Activity Number:
    Pharmacy Technician : 0428-0000-13-003-H01-T
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.